Anglo-Swedish drugmaker says availability of newer vaccines hit demand for jab
Continent’s drugmakers need to pay up to attract and retain talent, says Pascal Soriot
Michel Demaré in FT hits out at ISS and Glass Lewis for applying ‘double standards’ after they opposed CEO pay package
Double standards over pay do serious harm to our competitiveness in the war for talent
Almost 36 per cent of shareholders voted against a £1.8mn rise for the pharma group’s boss
GQG Partners argues that pharma group has performed strongly under long-serving chief
UK pharma group’s chief has a fresh challenge — persuading investors that its best days are not behind it
Shareholder advisory groups say potential £18.7mn payout is excessive
Acquisition gives pharmaceutical group mid-stage asset to challenge Novartis in new form of cancer care
Group of 11 pharma, tech and luxury shares echoes US dominance of ‘Magnificent Seven’
Best-selling Tagrisso drug slows progression of most common form of the disease at an early stage
Annual earnings at Anglo-Swedish pharma group miss expectations but revenues rise to $45.8bn
James Muir was discriminated against on the basis of his mental health disability
State aid package worth tens of millions of pounds expected as part of any agreement
Gracell Biotechnologies would operate as wholly owned subsidiary under terms of deal
Anglo-Swedish pharma group agrees to buy Seattle-based biotech Icosavax
Deal with Absci is the latest between big pharma and tech companies to build new disease treatments
Group plans to refocus on 30 core brands
Vaccine recipient claims he suffered side effect of severe blood clot
Anglo-Swedish drugmaker’s oncology and rare disease medication sales offset waning demand for Covid jabs
Drugmaker upbeat on full data after initial findings disappointed investors
Drugmaker says settlements will avoid costly litigation but claims are ‘without merit’
Anglo-Swedish group is latest to challenge Medicare’s new power to negotiate prices for a limited number of medicines
Drugmaker says it is working on new technologies to develop vaccines for infectious diseases where there is ‘high unmet need’
Drugmaker reports 38% jump in earnings as it expands genomic medicine business
International Edition